학술논문
SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
Document Type
article
Author
Maria Elena Lunati; Vincenzo Cimino; Alessandra Gandolfi; Matteo Trevisan; Laura Montefusco; Ida Pastore; Camilla Pace; Nazarena Betella; Giuseppe Favacchio; Monica Bulgheroni; Loredana Bucciarelli; Giulia Massari; Cristina Mascardi; Angela Girelli; Paola Silvia Morpurgo; Franco Folli; Livio Luzi; Marco Mirani; Basilio Pintaudi; Federico Bertuzzi; Cesare Berra; Paolo Fiorina
Source
Pharmacological Research, Vol 183, Iss , Pp 106396- (2022)
Subject
Language
English
ISSN
1096-1186
Abstract
Background and aims: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) may have important benefits for the elderly with type 2 diabetes (T2D), however some safety concerns still limit their use in patients over 70 years of age. The SOLD study (SGLT2i in Older Diabetic patients) is a multicenter study, aimed to evaluate the effectiveness and safety of SGLT2i in the older diabetic patients in a real-life setting. Materials and methods: We analyzed a population of 739 adults (mean age 75.4 ± 3.9 years, M/F 420/319) with T2D, which started a SGLT2i-based treatment after the age of 70, with at least one year of follow-up. Data were collected at baseline, at 6 and 12 months of follow-up. Results: SGLT2i (37.5% Empagliflozin, 35.7% Dapagliflozin, 26.1% Canagliflozin, 0.7% Ertugliflozin) were an add-on therapy to Metformin in 88.6%, to basal insulin in 36.1% and to other antidiabetic drugs in 29.6% of cases. 565 subjects completed the follow up, while 174 (23.5%) discontinued treatment due to adverse events which were SGLT2i related. A statistically significant reduction of glycated hemoglobin (baseline vs 12 months: 7.8 ± 1.1 vs 7.1 ± 0.8%, p